Effects of rosiglitazone on antagonizing insulin resistance and adipose liver damnification in hyperlipemic rats

Journal of Clinical Rehabilitative Tissue Engineering Research

Volumn 11, Issue 16, 2007, Pages

  Zheng, Lin Ying ^a   Pan, Jin Qiang ^a   Lin, Jie Ru ^a   Xiao, Liu Ying ^a   Li, Bo Ping ^a   Han, Chao ^a  

^a Guangzhou Hospital of Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE SALT; CARBOHYDRATE; CHOLESTEROL; CREATININE; FAT; GLICLAZIDE; GLUCOSE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LARD; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; NITROGEN; POLYSORBATE 80; PROPYLENE GLYCOL; PROTEIN; ROSIGLITAZONE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UREA; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY MASS; CHINESE MEDICINE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; FEEDING; FEMALE; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; RANDOMIZATION; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 34250647877     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003;52(4): 910-917
2. Viberti GC. Rosiglitazone: potential beneficial impact on cardiovascular disease. Int J Clin Pract 2003;57(2):128-134
3. Edvardsson U, Bergstrom M, Alexandersson M, et al. Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferators-like liver effects in obese mice. J Lipid Res 1999;40(7): 1177-1184
4. Tacikowski T, Nowicka G, Bujko J, et al. Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development Pol Arch Mad Wewn 2005;113(3):213-222
5. Zhang YM, Wei XB. The Experimental Model of Atherosclerosis. Beijing: Unite Publishing Company of Beijing Medical University-Peking Union Medical College 1998:1259-1272
6. Pan JQ, Guo JW, Li BP, et al. Pharmacological studies of antihypertensive drugs on improving insulin resistance. Guangdong Yaoxue 2002;12(1):1-5
7. Li QM, Zhang SH, Ren W, et al. Effect of rosiglitazone on insulin sensitivity and uncoupling protein gene mRNA expression in high fat rat model of insulin resistance. Zhengzhou Daxue Xuebao: Yixue Ban 2003; 38(7):374-377
8. Chen XP, Yang WY, Bu S, et al. Effects of rosiglitazone and metformin on insulin resistance in high fat diet rats. Zhonghua Yixue Zazhi 2004;43 (4):280-283
9. Liu Y, Gao XD, Xing WF. Effects of rosiglitazone maleate on type 2 diabetes. Zhongguo Yaoxue Zazhi 2003;38(7):511-514
10. Ye JM, Doyle PL, Iglesias MA, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activiation lowers muscle lipids and improves insulin sensitivily in high fat-fat rat: comparision with PPAR-gamma activation. Diabetes 2001;50(2):411
11. Pan JQ, Li BP, Guo JW, et al. Development on pharmacology of insulin sensitizing agents and insulin resistant animal models. Zhongguo Xinyao Zazhi 2001;10(9);654-657
12. Muurling M, van den Hoek AM, Mensink RP, et al. Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance. J Lipid Res 2004;46(1):9-16
13. Sun SJ, Shen ZF, Chen YT, et al. Effects of conjugated linoleic acid on obese MSG mice with insulin resistance. Acta Pharmaceutica Sinica 2003;38(12):904-907
14. Wang B, Li YM, Zhao XY, et al. Effects of rosiglitazone on insulin resistance in fructose-fed rats. Tianjin Yiyao 2004;32(4):233-234
15. Yosefy C, Megan E, Kiselevich A, et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44(2):215-222
16. Ryan MJ, Didion SP, Mathur S, et al. PPAR (gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004;43(3):661-666
17. Wang TD, Chen WJ, Lin JW, et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004;93(3):362-365
18. Li Q, Cheon YP, Kannan A, et al. A novel pathway involving progesterone receptor, lipoxygenase-derived eicosanoids, and peroxisorne proliferator-activated receptor gamma regulates. J Biol Chem 2004;279(12):11570-11581
19. Ding LX. Exploitation and clinical application of insulin potentiating agent. Shjie Linchuang Yaowu 2000;21(2):93-96
20. Cuzzocrea S, Pisana B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferators-activated teceptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Mad 2004;32(2):457-466